Mitchell Blutt, who is a leader in healthcare investments, was once a board member with the Michael J. Fox Foundation. As a member of the board, Mitchell Blutt had an in-depth look at the importance of developing a cure for Parkinson’s disease and finding volunteers for clinical trials.
Researchers spend much of their time developing treatments and prevention protocols for diseases. At the Michael J. Fox Foundation, scientists work every day to advance their research and innovations to help patients around the world. Unfortunately, sometimes their potential treatments never reach the trial stage. When this happens it is typically because of a lack of voluntary trial participants; 85% of trials are delayed and another 30% of trials are never launched because they lack participants.
The foundation is always seeking new volunteers for clinical trials. Therapies must be thoroughly tested within a large group of volunteer participants before the treatments can be approved and marketed to patients through normal medical treatment channels. Clinical trials are used to discover new approaches for preventing, diagnosing, and treating illnesses.
As an organization that has pushed the limits of traditional research methods, the foundation has transformed how healthcare professionals approach Parkinson’s disease. The foundation’s researchers plan to continue these transformations into the future in their quest to find a cure for Parkinson’s disease.